Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial

AIMS: A randomized, double-blind, placebo-controlled study was conducted to investigate the safety and efficacy of mipomersen, an apolipoprotein B-100 (apoB) synthesis inhibitor, in patients who are statin intolerant and at high risk for cardiovascular disease (CVD). METHODS AND RESULTS: Thirty-thre...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
मुख्य लेखकों: Visser, Maartje E., Wagener, Gilbert, Baker, Brenda F., Geary, Richard S., Donovan, Joanne M., Beuers, Ulrich H.W., Nederveen, Aart J., Verheij, Joanne, Trip, Mieke D., Basart, Dick C.G., Kastelein, John J.P., Stroes, Erik S.G.
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: Oxford University Press 2012
विषय:
Clinical Research
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC3751967/
https://ncbi.nlm.nih.gov/pubmed/22507979
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/eurheartj/ehs023
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन